Publications

5803 Results

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Authors
Wang X
Journal / Conference
Nat Commun. 2025 Nov 13;16(1):9968. doi: 10.1038/s41467-025-65016-3
Year
2025
Research Committee(s)
Melanoma
PMID
PMID41233329
PMC
PMC12615696
Study Number(s)
CTSU/E1609

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Authors
Zandberg DP
Journal / Conference
J Clin Oncol. 2025 Jul 20;43(21):2398-2408. doi: 10.1200/JCO-25-00759. Epub 2025 May 31.NIHMS2079170
Year
2025
PMID
PMID40448574
PMC
PMC12677393

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. Reply

Authors
Herrera AF
Journal / Conference
N Engl J Med. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID39752312
Study Number(s)
S1826

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Authors
A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;G Chatta;J Kim;M Bilen;B McGregor;P Singh;A Tripathi;S Cole;N Simon;S Niglio;L Ley;L Cordes;S Srinivas;J Huang;P Steen;M Odegaard;C Watt;D Petrylak;J Hoffman-Censits;Y Wen;O Hahn;C Mitchell;A Tan;H Streicher;E Sharon;H Moon;M Woods;S Halabi;G Burbano;M Morris;J Rosenberg
Journal / Conference
N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15.NIHMS2021479
Year
2025
Research Committee(s)
Genitourinary
PMID
PMID39282902
PMC
PMC11698643
Study Number(s)
CTSU/A031501

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Authors
E Bergsland;S Geyer;T Asmis;S Behr;P Kumthekar;M Maitland;D Niedzwiecki;A Nixon;L Schwartz;J Strosberg;A Venook;E O'Reilly;J Meyerhardt
Journal / Conference
J Clin Oncol. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3.NIHMS2099573
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID40902132
PMC
PMC12457709
Study Number(s)
CTSU/A021202

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Authors
B Andreadis;N Bartlett;J Leonard;P Stiff;J Friedberg;TBA
Journal / Conference
Leuk Lymphoma. 2025 Oct;66(10):1903-1912. doi: 10.1080/10428194.2025.2525982. Epub 2025 Jul 9.NIHMS2093959
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID40632607
PMC
PMC12321088
Study Number(s)
CTSU/A051301

Advanced Stage classical Hodgkin Lymphoma Patients with a Positive Interim-PET (PET-2) Deauville Score 5 After 2 ABVD Cycles: A Pooled Analysis of Three Multicenter Trials

Authors
S Viviani;S Pavoni;S Barrington;L Guerra;H Schoder;P Johnson;A Kirkwood;D Stephens;J Friedberg;S Chauvie;M Knopp;S Luminari;D Molin;P Corradini;A Gallamini;A Rambaldi;C Tarella
Journal / Conference
Blood Cancer Journal. 2025 Oct 16;15(1):165. doi: 10.1038/s41408-025-01364-z.
Year
2025
Research Committee(s)
Lymphoma
PMID
41102172
PMC
PMC12533113
Study Number(s)
S0816

Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned From Qualitative Content Analysis of S1316 - Comparative Effectiveness Trial for Malignant Bowel Obstruction

Authors
M Farooq;N Amini;V Sun;G Deutsch;J Deneve;M Grant;K Arnold;A Secord;G Anderson;R Krouse
Journal / Conference
Am J Hosp Palliat Care. 2025 Oct 29:10499091251391420. doi: 10.1177/10499091251391420. Online ahead of print.
Year
2025
Research Committee(s)
Palliative Care
PMID
41159270
Study Number(s)
S1316

The Influence of Age on Patient-Reported Outcomes (PROs) Endpoints on the S1826 Cross-Network Phase III trial of Advanced-Stage, Classic Hodgkin Lymphoma (cHL) (3891/4500)

Authors
K Davison;J Unger;H Li;S Castellino;H Dillon;T Hernandez;S Rutherford;A Punnett;M LeBlanc;J Song;S Smith;A Evens;K Kelly;J Friedberg;A Herrera;S Parsons
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL)
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy (Alliance A041701)

Authors
G Uy;J Yin;S Dinner;D DeAngelo;J Liesveld;J Kolitz;A Asch;O Odenike;O Kour;R Teske;K Skogen;K Byrd;R Little;A Carroll;K Mrozek;A Eisfeld;J Byrd;A Jaslowski;H Erba;M Litzow;W Stock;R Stone
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL)
Year
2025
Research Committee(s)
Leukemia